CA2877989C - Shortened cd95-fc variants - Google Patents

Shortened cd95-fc variants Download PDF

Info

Publication number
CA2877989C
CA2877989C CA2877989A CA2877989A CA2877989C CA 2877989 C CA2877989 C CA 2877989C CA 2877989 A CA2877989 A CA 2877989A CA 2877989 A CA2877989 A CA 2877989A CA 2877989 C CA2877989 C CA 2877989C
Authority
CA
Canada
Prior art keywords
fusion protein
seq
domain
protein according
functional fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2877989A
Other languages
English (en)
French (fr)
Other versions
CA2877989A1 (en
Inventor
Oliver Hill
Christian Gieffers
Meinolf Thiemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apogenix AG
Original Assignee
Apogenix AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix AG filed Critical Apogenix AG
Publication of CA2877989A1 publication Critical patent/CA2877989A1/en
Application granted granted Critical
Publication of CA2877989C publication Critical patent/CA2877989C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
CA2877989A 2012-07-18 2013-07-18 Shortened cd95-fc variants Expired - Fee Related CA2877989C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12176978.0 2012-07-18
EP12176978 2012-07-18
EP12176980 2012-07-18
EP12176980.6 2012-07-18
PCT/EP2013/065248 WO2014013037A1 (en) 2012-07-18 2013-07-18 Shortened cd95-fc variants

Publications (2)

Publication Number Publication Date
CA2877989A1 CA2877989A1 (en) 2014-01-23
CA2877989C true CA2877989C (en) 2021-05-25

Family

ID=48794121

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2877989A Expired - Fee Related CA2877989C (en) 2012-07-18 2013-07-18 Shortened cd95-fc variants
CA2878992A Active CA2878992C (en) 2012-07-18 2013-07-18 Composition comprising a mixture of cd95-fc isoforms

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2878992A Active CA2878992C (en) 2012-07-18 2013-07-18 Composition comprising a mixture of cd95-fc isoforms

Country Status (18)

Country Link
US (5) US9434783B2 (https=)
EP (4) EP3409686B1 (https=)
JP (2) JP6317739B2 (https=)
KR (1) KR102201694B1 (https=)
CN (3) CN109897115A (https=)
AU (2) AU2013291984B2 (https=)
BR (1) BR112015000732B1 (https=)
CA (2) CA2877989C (https=)
DK (2) DK2875045T3 (https=)
ES (2) ES2924109T3 (https=)
HK (1) HK1207095A1 (https=)
IL (1) IL236659A (https=)
MX (1) MX371430B (https=)
NZ (1) NZ703546A (https=)
RU (2) RU2648146C2 (https=)
SG (1) SG11201500134QA (https=)
UA (1) UA116889C2 (https=)
WO (2) WO2014013039A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3409686B1 (en) * 2012-07-18 2022-04-13 Apogenix AG Composition comprising a mixture of cd95-fc isoforms
CN105393121B (zh) * 2013-04-29 2018-04-24 阿珀吉尼科斯股份公司 诊断癌症的方法
NO2776305T3 (https=) * 2014-04-23 2018-01-27
EP3137909B1 (en) 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
US9587215B2 (en) 2014-08-07 2017-03-07 General Electric Company Devices, systems and methods for automated transfer of a sample
EP3236772A4 (en) * 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
US20220177841A1 (en) 2019-03-29 2022-06-09 Myst Therapeutics Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
US20230032934A1 (en) 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
CN114829371A (zh) * 2019-12-12 2022-07-29 Emd密理博公司 使用透析过滤缓冲液强化的病毒过滤
EP4512828A3 (en) 2020-02-27 2025-05-14 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
LT3972987T (lt) * 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
CN115894706A (zh) * 2021-09-30 2023-04-04 北京康辰药业股份有限公司 靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production
WO2026073032A1 (en) 2024-09-27 2026-04-02 Shape Therapeutics Inc. Constructs for improved aav production

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306395B1 (en) 1996-05-02 2001-10-23 Mochida Pharmaceutical Co., Ltd. Fas antigen derivatives
CA2270423C (en) * 1996-10-31 2009-09-15 Mochida Pharmaceutical Co., Ltd. Prophylactic/therapeutic agent
DE69839582D1 (de) * 1997-02-27 2008-07-17 Ono Pharmaceutical Co Neues polypeptid, dafür kodierende dna und deren verwendungen
CA2309598A1 (en) * 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung disease
RU2420537C2 (ru) * 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
EP1273297A1 (en) * 2001-07-06 2003-01-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction)
PT1606318E (pt) * 2003-03-26 2009-11-10 Deutsches Krebsforsch Proteínas de fusão de fc melhoradas
US20100215637A1 (en) * 2006-03-28 2010-08-26 Biopharmica Ltd Agent for the Treatment of Hormone-Dependent Disorders and Uses Thereof
WO2007147600A2 (en) * 2006-06-21 2007-12-27 Apogenix Gmbh Differential il-4 and/or il-10 cytokine expression in human cancer
SI2428252T1 (sl) * 2006-12-28 2015-01-30 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Nevtralizacija invazije aktivnostnih blokov cd95 v celicah glioblastoma in vivo
WO2008101671A2 (en) * 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
EP2009022A1 (en) * 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
WO2010003766A2 (en) 2008-06-17 2010-01-14 Apogenix Gmbh Multimeric tnf receptors
US8664366B2 (en) * 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
CN102497886B (zh) * 2009-07-21 2016-01-20 玛丽皇后与斯特菲尔德学院 用于细胞内药物递送的Fas(Apo-1，CD95)靶向平台
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
EP3409686B1 (en) * 2012-07-18 2022-04-13 Apogenix AG Composition comprising a mixture of cd95-fc isoforms
CN105393121B (zh) * 2013-04-29 2018-04-24 阿珀吉尼科斯股份公司 诊断癌症的方法

Also Published As

Publication number Publication date
JP6231562B2 (ja) 2017-11-15
US9908928B2 (en) 2018-03-06
US20150166633A1 (en) 2015-06-18
US9315570B2 (en) 2016-04-19
RU2648146C2 (ru) 2018-03-22
RU2015105330A (ru) 2016-09-10
SG11201500134QA (en) 2015-03-30
US9434783B2 (en) 2016-09-06
US10370441B2 (en) 2019-08-06
EP2875045A1 (en) 2015-05-27
WO2014013037A1 (en) 2014-01-23
RU2648157C2 (ru) 2018-03-22
NZ703546A (en) 2018-03-23
IL236659A (en) 2017-02-28
MX2015000731A (es) 2015-09-04
HK1207095A1 (en) 2016-01-22
IL236659A0 (en) 2015-02-26
HK1207096A1 (en) 2016-01-22
DK3409686T3 (da) 2022-07-18
AU2013291984A1 (en) 2015-02-05
US20150225475A1 (en) 2015-08-13
MX371430B (es) 2020-01-30
CA2878992C (en) 2020-09-22
EP3406630B1 (en) 2020-09-02
ES2674662T3 (es) 2018-07-03
EP2875045B1 (en) 2018-03-28
EP2875044B1 (en) 2018-04-11
DK2875045T3 (en) 2018-07-02
CN109897115A (zh) 2019-06-18
WO2014013039A1 (en) 2014-01-23
CN104662039B (zh) 2019-10-08
EP3406630A1 (en) 2018-11-28
CA2877989A1 (en) 2014-01-23
US20160362471A1 (en) 2016-12-15
US9657083B2 (en) 2017-05-23
RU2015105328A (ru) 2016-09-10
ES2924109T3 (es) 2022-10-04
JP2015524403A (ja) 2015-08-24
KR20150048120A (ko) 2015-05-06
JP6317739B2 (ja) 2018-04-25
EP3409686B1 (en) 2022-04-13
EP2875044A1 (en) 2015-05-27
UA116889C2 (uk) 2018-05-25
AU2013291982B2 (en) 2017-01-12
JP2015528006A (ja) 2015-09-24
CA2878992A1 (en) 2014-01-23
US20180186856A1 (en) 2018-07-05
CN104662039A (zh) 2015-05-27
AU2013291982A1 (en) 2015-02-05
BR112015000732B1 (pt) 2023-01-10
BR112015000732A2 (https=) 2017-08-15
KR102201694B1 (ko) 2021-01-12
CN104640876A (zh) 2015-05-20
EP3409686A1 (en) 2018-12-05
AU2013291984B2 (en) 2018-01-18
US20160235815A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
CA2877989C (en) Shortened cd95-fc variants
JP6055615B2 (ja) Ｄａｃｈｙｐ組成物および方法
JP2021073229A (ja) 選択的ｉｌ−６−トランス−シグナル伝達阻害剤組成物
HK40005359A (en) Composition comprising a mixture of cd95-fc isoforms
HK1207096B (zh) 缩短的cd95-fc变体

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180320

MKLA Lapsed

Effective date: 20220718